Insider Transactions in Q3 2023 at Kiniksa Pharmaceuticals, Ltd. (KNSA)
Insider Transaction List (Q3 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 05
2023
|
John F. Paolini CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
400
-0.88%
|
$6,800
$17.53 P/Share
|
|
Sep 05
2023
|
John F. Paolini CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
400
+0.88%
|
$400
$1.86 P/Share
|
|
Sep 02
2023
|
Eben Tessari CHIEF OPERATING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
577
-0.47%
|
$9,809
$17.76 P/Share
|
|
Sep 02
2023
|
Eben Tessari CHIEF OPERATING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,964
+1.56%
|
-
|
|
Sep 02
2023
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
547
-3.38%
|
$9,299
$17.76 P/Share
|
|
Sep 02
2023
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,861
+10.32%
|
-
|
|
Sep 02
2023
|
Sanj K Patel CHAIRMAN & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,187
-4.0%
|
$37,179
$17.76 P/Share
|
|
Sep 02
2023
|
Sanj K Patel CHAIRMAN & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
6,569
+10.72%
|
-
|
|
Sep 02
2023
|
Ross Moat CHIEF COMMERCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
543
-3.63%
|
$9,231
$17.76 P/Share
|
|
Sep 02
2023
|
Ross Moat CHIEF COMMERCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
994
+6.23%
|
-
|
|
Sep 02
2023
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
228
-1.33%
|
$3,876
$17.76 P/Share
|
|
Sep 02
2023
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
774
+4.33%
|
-
|
|
Sep 02
2023
|
John F. Paolini CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
507
-1.12%
|
$8,619
$17.76 P/Share
|
|
Sep 02
2023
|
John F. Paolini CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,725
+3.66%
|
-
|
|
Sep 01
2023
|
Eben Tessari CHIEF OPERATING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
801
-0.65%
|
$13,617
$17.76 P/Share
|
|
Sep 01
2023
|
Eben Tessari CHIEF OPERATING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,727
+2.17%
|
-
|
|
Sep 01
2023
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
791
-5.24%
|
$13,447
$17.76 P/Share
|
|
Sep 01
2023
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,695
+15.14%
|
-
|
|
Sep 01
2023
|
Sanj K Patel CHAIRMAN & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,432
-8.43%
|
$75,344
$17.76 P/Share
|
|
Sep 01
2023
|
Sanj K Patel CHAIRMAN & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
9,992
+15.97%
|
-
|
|
Sep 01
2023
|
Ross Moat CHIEF COMMERCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,353
-8.83%
|
$23,001
$17.76 P/Share
|
|
Sep 01
2023
|
Ross Moat CHIEF COMMERCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,477
+13.92%
|
-
|
|
Sep 01
2023
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,155
-6.6%
|
$19,635
$17.76 P/Share
|
|
Sep 01
2023
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,933
+18.36%
|
-
|
|
Sep 01
2023
|
John F. Paolini CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
734
-1.65%
|
$12,478
$17.76 P/Share
|
|
Sep 01
2023
|
John F. Paolini CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,498
+5.33%
|
-
|
|
Jul 25
2023
|
John F. Paolini CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
29,000
-15.78%
|
$522,000
$18.98 P/Share
|
|
Jul 25
2023
|
John F. Paolini CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
29,000
+29.03%
|
$29,000
$1.86 P/Share
|
|
Jul 15
2023
|
Ross Moat CHIEF COMMERCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
292
+2.22%
|
$3,504
$12.35 P/Share
|
|
Jul 15
2023
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
581
+4.11%
|
$6,972
$12.35 P/Share
|